NMN, or nicotinamide mononucleotide, is a nucleotide and NAD+ precursor found in human biology that has been studied in human trials mainly for raising NAD-related biomarkers and for possible effects on insulin sensitivity, exercise performance, sleep-related outcomes, and other aging-related physiological measures (Research) (Research).
Human research on NMN is still developing rather than settled. Multiple oral supplementation studies report increases in blood or whole-blood NAD-related measures, but clinical outcomes are more variable across populations and endpoints, and recent reviews describe the literature as promising but limited by short duration, small samples, and heterogeneous study designs (Research) (Review). Topical NMN is also gaining skincare attention, but NMN-specific skin evidence is currently much earlier-stage than oral NMN evidence and consists mainly of artificial membrane permeability testing, reconstructed human skin models, human skin-cell studies, and animal photoaging research rather than direct human topical cosmetic trials (Research) (Research).
Ingredient Identity
- Official name(s): Nicotinamide mononucleotide; β-nicotinamide mononucleotide
- Synonyms: NMN; β-NMN
- Classification: Nucleotide; NAD+ biosynthesis intermediate (Research)
- Endogenous vs exogenous: NMN is an endogenous biochemical intermediate and has also been studied as an exogenous oral ingredient in clinical trials (Research)
- Primary research context: Human studies mainly evaluate oral NMN as an NAD+ precursor; topical NMN is an emerging skincare research topic but has not yet developed a comparable human clinical evidence base (Research) (Research)
Ingredient Snapshot
- Classification: NMN is a nucleotide intermediate in NAD+ biosynthesis (Research).
- Endogenous vs exogenous status: NMN occurs in human biochemistry and has also been studied as an oral supplemental ingredient in clinical trials (Research).
- Primary human research domains: Human studies have focused on NAD-related biomarkers, insulin sensitivity, muscle and exercise performance, sleep-related measures, and broader aging-related functional outcomes (Research) (Research).
- Topical skin research status: Topical NMN is an emerging skincare-interest area, but NMN-specific evidence is currently mainly preclinical, model-based, or formulation-based rather than direct human topical efficacy evidence (Research) (Research).
- Common study formats: The clinical literature is dominated by oral supplementation trials, dose-ranging studies, and short-term safety or biomarker studies (Research) (Research).
- Pharmacokinetic characterization status: Human evidence supports measurable biomarker change after oral administration, but the available literature is stronger for NAD-related response than for a complete classical pharmacokinetic profile (Research).
- Regulatory context, U.S.: NIH ODS notes FDA’s November 2022 position that NMN may not be legally marketed as a dietary supplement because it had been authorized for investigation as a new drug (NIH ODS).
- Regulatory context, EU: European Commission material describes NMN in the novel food framework (EFSA).
- Evidence maturity: Evidence is best described as emerging to moderate for oral NMN, with repeated biomarker findings but mixed clinical-outcome results and generally short trials (Review) (Review).
Introduction
NMN is a small molecule in the vitamin B3 / NAD+ pathway, and it is studied because NAD+ is involved in cellular energy metabolism and other basic biological processes (Research). Human trials support describing NMN as an endogenous NAD+ precursor that can also be administered orally in clinical research (Research).
People look up NMN because researchers have tested whether raising NAD-related biomarkers translates into measurable changes in insulin sensitivity, exercise performance, fatigue, sleep quality, or other aging-related outcomes (Research) (Review). NMN is also appearing in skincare discussions because skin aging research increasingly involves NAD+ biology, oxidative stress, barrier function, collagen biology, and cellular energy, but NMN-specific topical evidence remains early and should not be treated like established topical niacinamide evidence (Research) (Review).
This article is informational only, describes NMN as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- NMN is a nucleotide precursor of NAD+ that has been studied in humans mainly to assess whether oral supplementation raises NAD-related biomarkers and influences metabolic, functional, or aging-related outcomes (Research).
- The most consistent human finding is that oral NMN can increase blood or whole-blood NAD-related measures, while outcome benefits are more variable across studies (Research) (Research).
- Topical NMN is receiving skincare attention, but direct human topical NMN clinical evidence remains limited; the current NMN-specific skin evidence is mainly artificial membrane, reconstructed human skin, cell-model, and animal research (Research) (Research).
- One targeted randomized trial reported improved muscle insulin sensitivity in overweight or obese postmenopausal women with prediabetes given 250 mg/day for 10 weeks (Research).
- Trials in older adults have reported positive findings for lower-limb function, drowsiness, sleep quality, or walking-related outcomes in some settings, but not all studies have found clear functional improvement (Research) (Research).
- Short-term human studies generally describe oral NMN as well tolerated across commonly studied supplemental ranges, including dose-ranging work up to 900 mg/day and a short-term 1250 mg/day safety study (Research) (Research).
- For skincare, NMN should be distinguished from niacinamide: niacinamide has direct topical human cosmetic trials, while topical NMN currently has earlier-stage supporting evidence (Review).
Human Research Findings by Condition
Aging and Longevity Research
Human research in aging-related contexts has mainly examined whether oral NMN raises NAD-related biomarkers and whether that is accompanied by changes in physical function, fatigue, or other age-associated measures (Research). The overall signal is mixed: several studies report biomarker or selected functional improvements, but the human literature does not yet establish broad anti-aging clinical effects (Review).
Key human study
Dose studied: 250 mg/day
Population: Healthy older men
Duration: 6 or 12 weeks
Researchers studied chronic oral NMN supplementation in healthy older men and reported increases in whole-blood NAD-related metabolites along with changes in muscle-function-related measures (Research). This study connects repeated daily dosing with measurable biomarker change in an older population rather than relying only on acute administration data (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 250 mg/day
Population: Older adults
Duration: 12 weeks
A 12-week trial in older adults examined NMN intake timing and reported improvement in lower-limb function and reduced drowsiness, particularly with afternoon intake (Research). This adds functional aging-related context, although the outcomes are narrower than a broad longevity claim (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Diabetes and Glycemic Control
Several human studies and reviews have examined NMN in glucose-related or insulin-related settings (Research). The strongest targeted result comes from a specific prediabetic population, while broader pooled analyses across mixed adult samples report more limited or mixed findings for glucose and lipid outcomes (Review).
Key human study
Dose studied: 250 mg/day
Population: Overweight or obese postmenopausal women with prediabetes
Duration: 10 weeks
This randomized trial examined whether NMN affected skeletal muscle insulin action and reported improved muscle insulin sensitivity and insulin signaling (Research). It is one of the clearest targeted efficacy findings in the human NMN literature, but it comes from a defined metabolic subgroup rather than a broad general population (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: Multiple dose ranges across included randomized trials
Population: Adults across pooled randomized controlled trials
Duration: Short-term trials pooled in review
A 2024 review and meta-analysis reported that short-term NMN supplementation did not show significantly positive overall effects on glucose control and lipid profile across included studies (Review). This broader synthesis helps explain why enthusiasm based on individual positive trials remains tempered (Review).
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Review)
Muscle Health
Research in human populations has evaluated NMN for exercise performance, walking-related measures, and muscle-function-associated outcomes using multiple study designs (Research) (Research). The overall picture is encouraging in some groups but not uniform across all populations or endpoints (Research).
Key human study
Dose studied: 300 mg, 600 mg, or 1200 mg/day
Population: Amateur runners
Duration: 6 weeks
A randomized double-blind study in amateur runners reported that NMN supplementation enhanced aerobic capacity during exercise training (Research). This is relevant to muscle and exercise performance, but it reflects a trained population and short study duration (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: Daily oral NMN supplementation
Population: Older male patients with diabetes and impaired physical performance
Duration: 24 weeks
This placebo-controlled study reported that NMN supplementation was safe but did not improve grip strength or walking speed (Research). It is one of the clearest neutral trials in the human source set and is important because it tempers broad performance claims (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
Sleep
Sleep-related evidence for NMN is limited but present. Human studies in older adults have examined sleep quality, drowsiness, and fatigue-related measures, and some trials reported positive changes, but this remains a small research area compared with NAD biomarkers or metabolic outcomes (Research) (Research).
Key human study
Dose studied: 250 mg/day
Population: Older adults
Duration: 12 weeks
This study investigated sleep quality, fatigue, and physical performance in older adults and reported reduced drowsiness with time-dependent intake (Research). The result is relevant because it shows that NMN has been evaluated for subjective sleep-related outcomes rather than only laboratory biomarkers (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: 250 mg/day
Population: Older adults
Duration: 12 weeks
A randomized placebo-controlled study reported increased blood NAD and improvements in sleep quality while also helping maintain walking speed (Research). This supports the idea that sleep-related outcomes have been explored in older adults, but the literature remains too small for a strong classification (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Cardiovascular Health
Cardiovascular and cardiometabolic evidence in human NMN research is weaker than the evidence for NAD-related biomarker change or the targeted insulin-sensitivity trial (Review). Some analyses touch lipid-related or broader cardiometabolic markers, but the better-supported conclusion is that cardiovascular claims remain preliminary and mixed (Review).
Key human study
Dose studied: Multiple dose ranges across pooled randomized trials
Population: Adults across pooled randomized controlled trials
Duration: Short-term trials pooled in review
The 2024 review and meta-analysis on glucose and lipid metabolism did not find significantly positive overall effects on lipid profile (Review). Because cardiovascular supplement claims often lean on lipid or cardiometabolic surrogates, this pooled result supports a cautious interpretation (Review).
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Review)
Additional human study
Dose studied: Various doses across pooled studies
Population: Middle-aged and elderly adults in pooled analyses
Duration: Pooled human trials
A separate 2024 meta-analysis reported positive pooled effects for some measures, including insulin resistance and aminotransferase markers in middle-aged and elderly individuals (Review). That finding suggests a broader cardiometabolic signal, but it is not the same as firm cardiovascular clinical evidence (Review).
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Review)
Beauty and Skin Health
Topical NMN is an emerging skincare research topic, but the NMN-specific evidence is not yet comparable to topical niacinamide’s human cosmetic evidence (Research) (Review). Current NMN-specific skin evidence mainly comes from artificial membrane permeability testing, reconstructed human skin models, human skin-cell experiments, and animal photoaging work rather than direct human topical trials measuring wrinkles, hydration, firmness, pigmentation, or barrier outcomes (Research) (Research).
Key topical research context
Dose studied: NMN in yeast-fermented filtrate; cosmetic permeability model
Population: Artificial skin membrane and human fibroblast laboratory models, not a human clinical trial
Duration: Formulation, permeability, stability, and cell-assay testing
A 2025 cosmetic permeability study evaluated NMN in a yeast-fermented filtrate using an artificial Strat-M skin membrane, MALDI imaging, fibroblast collagen Type I testing, and stability analysis (Research). The study reported that NMN permeated the artificial membrane model and was associated with increased collagen Type I production in fibroblast testing, but this does not prove visible skin benefit in living human skin (Research).
Result: Evidence currently comes mainly from animal or experimental research
Evidence strength: Emerging
Study source: (Research)
Additional topical research context
Dose studied: NMN in reconstructed human skin with aged melanocytes
Population: Reconstituted human skin model, not a human clinical trial
Duration: Laboratory pigmentation model
A 2022 study used reconstituted human skin with aged melanocytes and reported that NMN reduced melanin production in that model (Research). This is relevant to pigmentation biology, but it should not be presented as proof that topical NMN lightens hyperpigmentation in people (Research).
Result: Evidence currently comes mainly from animal or experimental research
Evidence strength: Emerging
Study source: (Research)
Dosage & Study Snapshot (Research Context)
The human NMN literature is mainly oral supplemental, with acute administration studies, repeated daily dosing trials, dose-ranging studies, and short-term safety studies (Research) (Research). Topical NMN dosing cannot currently be summarized as an evidence-based human skincare dose range because the available NMN-specific topical evidence is mainly artificial membrane, reconstructed skin, and cell-model research rather than direct human topical trials (Research).
Topical NMN formulation research, no established human topical dose range:
A 2025 topical NMN study examined NMN in a yeast-fermented filtrate using an artificial skin membrane model and human fibroblast testing, rather than testing a consumer topical product in a human cosmetic trial (Research). The study is useful for formulation science because it evaluated permeation, localization, collagen Type I production in fibroblasts, and NMN stability in the tested filtrate (Research). It does not establish an effective human topical percentage for wrinkles, pigmentation, hydration, or barrier repair (Research). The most accurate skincare-dose statement is that topical NMN has early permeability and formulation evidence, but no clearly established human topical dose range (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This is not a human topical efficacy dose band.
Single oral administration:
An acute oral administration study in healthy Japanese men examined NMN’s immediate effects on clinical parameters and nicotinamide metabolite levels (Research). This is an early human exposure context and shows that oral NMN enters measurable human metabolic pathways (Research). Because it was an acute study, it is more useful for exposure and short-term tolerability context than for sustained clinical-benefit claims (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Acute dosing helps establish biological activity but does not answer long-term efficacy questions.
250 mg/day:
This is the best-supported recurring chronic dose in the human literature used here (Research). Studies at 250 mg/day in older adults, healthy older men, and a targeted prediabetic postmenopausal population reported increases in NAD-related biomarkers and, in some trials, improvements in insulin sensitivity, lower-limb function, drowsiness, sleep quality, or maintained walking-related performance (Research) (Research). The findings are not identical across populations, but this band is the clearest anchor for repeated-dose interpretation (Research).
Result: Modest improvement
Evidence strength: Moderate
Notes / limitations: Positive results at this dose depend on population and endpoint and should not be generalized to all outcomes.
300–900 mg/day:
A multicenter randomized placebo-controlled clinical trial in healthy middle-aged adults reported that NMN increased blood NAD concentrations and was safe and well tolerated with oral dosing up to 900 mg/day (Research). This dose band is especially useful because it represents higher conventional supplement-style exposure, but the clearest result in this range is biomarker change rather than definitive broad clinical benefit (Research).
Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: The strongest evidence in this band concerns blood NAD response rather than broad efficacy across multiple clinical endpoints.
1250 mg/day:
A short-term safety study reported that β-NMN was safe and well tolerated in healthy adult men and women at 1250 mg once daily for up to 4 weeks (Research). This higher-dose band is informative mainly for tolerability context and should not be read as proof that higher doses yield proportionally greater clinical benefit (Research).
Result: Neutral overall findings
Evidence strength: Limited
Notes / limitations: This dose band mainly informs short-term safety rather than efficacy.
Key Takeaways from Human Research
- The most reproducible human NMN finding is an increase in blood or whole-blood NAD-related biomarkers after oral supplementation (Research) (Research).
- The strongest targeted clinical result in this evidence set is improved muscle insulin sensitivity in overweight or obese postmenopausal women with prediabetes at 250 mg/day for 10 weeks (Research).
- Topical NMN is an emerging skincare topic, but NMN-specific topical evidence is currently early-stage and does not establish a human cosmetic efficacy dose (Research).
- Findings for muscle performance and exercise-related outcomes are encouraging in some groups, including amateur runners and some older adults, but they are not consistent across all studies (Research) (Research).
- Sleep and fatigue-related outcomes have shown preliminary positive signals in older adults, but this remains a smaller evidence area than biomarker or metabolic research (Research) (Research).
- Short-term tolerability is reasonably well supported, but long-term safety, rare adverse events, and detailed interaction risk remain undercharacterized (Research) (Review).
Origin & Natural Occurrence
NMN is an endogenous intermediate in the NAD+ biosynthetic pathway, which means it is part of normal human biochemistry as well as a manufactured research and commercial ingredient (Research). European Commission novel-food consultation material also describes NMN production through enzymatic manufacturing technology for ingredient use (EFSA).
How It Behaves in the Body
In plain language, NMN is studied as a way to supply the body with material that can help rebuild NAD+, a molecule involved in energy metabolism and other cellular housekeeping processes (Research). Human studies repeatedly show that oral NMN can raise blood or whole-blood NAD-related markers, which is the clearest indication that the compound is biologically active after ingestion (Research) (Research).
Mechanistically, NMN is an intermediate in the NAD+ salvage pathway (Research). That matters because lower NAD-related status has been studied in relation to aging and metabolic dysfunction, which is why human trials have focused on insulin sensitivity, exercise-related performance, and older-adult functional measures (Review).
For skin, the proposed rationale is also tied to NAD+ biology, cellular energy, oxidative stress, and repair pathways, but NMN-specific topical evidence is not yet a mature human clinical field (Research) (Research). It is more accurate to say that topical NMN has early formulation and skin-model support than to say it has proven visible anti-aging effects in humans (Research).
Absorption & Delivery Formats
Oral immediate-release: This is the best-studied delivery format in the human evidence base. Acute and repeated oral studies show that NMN can affect measured nicotinamide metabolite or NAD-related biomarkers in humans (Research) (Research).
Oral extended-release: The current evidence base does not provide a clearly supported extended-release clinical evidence base, so evidence is limited in this format.
Sublingual: The current evidence base does not provide directly supported human sublingual trial evidence, so evidence is limited.
Topical / transdermal: Topical NMN has early formulation and permeability evidence from an artificial skin membrane model, but direct human topical clinical outcomes remain limited (Research). The available evidence does not establish a validated human transdermal NMN dose or a confirmed topical cosmetic dose-response curve (Research).
Injectable / IV: The current evidence base used here does not provide directly supported human injectable or intravenous NMN evidence.
Quick Facts at a Glance
Onset, oral studies:
The clearest onset evidence comes from acute oral administration and short-duration biomarker studies, which show that NMN can alter measured nicotinamide metabolite or NAD-related markers after ingestion (Research). Precise clinical onset for outcomes such as sleep, function, or insulin sensitivity is not established because those outcomes were studied over weeks rather than hours (Research) (Research).
Topical onset:
Topical NMN onset for visible human skin outcomes is not established because direct human topical NMN cosmetic trials are not yet a mature evidence area (Research). Current topical NMN evidence is mainly formulation and model-based rather than clinical-onset evidence in people (Research).
Time to peak (Tmax):
A conventional drug-style Tmax is not robustly characterized in the oral NMN evidence set used here. The available studies support measurable biomarker change after oral administration, but they do not establish a clean, widely accepted Tmax summary for routine clinical or consumer interpretation (Research).
Half-life:
The current human evidence set does not provide a settled clinical half-life value suitable for a firm standalone summary. This is one reason the human literature is stronger for “does it raise NAD-related biomarkers” than for formal pharmacokinetic characterization (Research).
Typical duration:
Most human trials in this evidence base are short, ranging from acute administration to about 4 weeks, 6 weeks, 10 weeks, 12 weeks, and one 24-week study (Research) (Research). The literature is therefore better at describing short-term response and tolerability than long-term durability (Review).
Absorption routes studied:
The human evidence is overwhelmingly oral. Topical evidence is currently based on artificial membrane and skin-model research rather than direct human topical absorption or efficacy trials (Research).
Formulation differences:
The clinical oral literature includes acute oral exposure, repeated daily oral supplementation, and short-term higher-dose safety work (Research) (Research). Topical NMN formulations should not be assumed equivalent to oral NMN because topical performance depends on vehicle, skin penetration, stability, and local tissue exposure (Research).
Variability drivers:
Results vary by population, dose, study duration, and endpoint (Review). Positive findings are clearer in some defined groups, such as postmenopausal women with prediabetes or selected older-adult cohorts, than in pooled analyses across mixed adults (Research).
Tolerance / adaptation:
The current evidence set does not provide strong evidence for tolerance or loss of effect over time in the way that term is commonly used for drugs. Repeated short-term oral use generally remained tolerated in the published trials available here (Research) (Research).
Evidence strength snapshot:
Evidence is strongest for oral NAD-related biomarker change, moderate for a few targeted metabolic or functional outcomes, and weaker for broad claims about general anti-aging or cardiometabolic benefit (Review) (Review). Topical NMN evidence is best classified as early-stage because direct human topical cosmetic trials are not yet available in the same way they are for niacinamide (Research) (Review).
Safety, Interactions & Regulation
Human safety data are mostly short-term, but they are reasonably consistent in describing oral NMN as well tolerated in healthy adults and in several supplementation trials (Research) (Research) (Research). The main caution is not a strong signal of frequent serious adverse effects in the available studies, but the limited size and duration of the evidence base (Review).
Topical NMN safety cannot be summarized from a mature human clinical-trial base because current NMN-specific topical evidence is mostly formulation or model-based (Research). Topical tolerability should therefore be interpreted product-by-product rather than inferred from oral NMN studies or from topical niacinamide studies (Review).
The current evidence set does not contain a strong direct human interaction library, so medication-interaction claims are best described as insufficiently characterized rather than clearly established.
In the United States, NIH ODS notes FDA’s November 2022 position that NMN may not be legally marketed as a dietary supplement because it had been authorized for investigation as a new drug (NIH ODS). In the European Union, Commission consultation material states that NMN is considered a novel food because prior EU consumption before 15 May 1997 had not been established (EFSA).
Evidence Overview
The current human evidence base for NMN is strongest in oral NAD-related biomarker response, where multiple studies show that NMN can raise blood or whole-blood NAD-related measures (Research) (Research). The clearest targeted clinical outcome is muscle insulin sensitivity in overweight or obese postmenopausal women with prediabetes, where a randomized trial reported significant improvement at 250 mg/day for 10 weeks (Research). Confidence is not higher because the published trial base remains small, short, and heterogeneous (Review).
Across the rest of the oral literature, the pattern is mixed rather than uniformly positive. Some studies in older adults report favorable changes in lower-limb function, drowsiness, sleep quality, or maintained walking-related measures, and a trial in amateur runners reported improved aerobic-capacity-related outcomes during exercise training (Research) (Research) (Research). At the same time, a 24-week trial in older men with diabetes and impaired physical performance did not find clear improvement in grip strength or walking speed (Research).
The topical NMN evidence should be handled separately from the oral evidence. Current NMN-specific topical support comes from artificial membrane permeability testing, reconstructed human skin pigmentation models, human skin-cell assays, and animal photoaging research rather than direct human topical cosmetic trials (Research) (Research). This is enough to justify a cautious “emerging topical research” discussion, but not enough to claim that topical NMN improves wrinkles, pigmentation, hydration, or firmness in humans (Research).
The comparison with niacinamide is useful but must be kept precise. Niacinamide, also called nicotinamide, has direct topical human cosmetic evidence for skin aging and hyperpigmentation, while NMN is a different NAD-related compound with a less mature topical evidence base (Review) (Research). Future research would strengthen the topical NMN evidence by testing defined NMN concentrations in randomized human facial-skin studies with validated endpoints such as wrinkles, pigmentation, hydration, barrier function, redness, and tolerability.
Evidence Confidence Classification
The overall human evidence for oral NMN is Moderate, based on multiple human studies showing consistent NAD-related biomarker effects and a smaller number of targeted positive clinical findings, but with important limitations in study size, duration, and consistency across endpoints (Research) (Review).
The evidence for topical NMN in skin and beauty is Emerging, because the NMN-specific evidence is currently mainly formulation, artificial membrane, reconstructed skin, cell, and animal research rather than direct human topical efficacy trials (Research) (Research). This distinction matters because oral NMN biomarker evidence should not be used as proof of topical NMN skincare efficacy.
The overall classification is not Strong because the clinical literature still contains mixed results and relies heavily on short trials (Research) (Review). It is stronger than purely Emerging for oral NMN because the current evidence includes repeated human supplementation studies, randomized designs, and multiple 2024 syntheses (Review).
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Nicotinamide riboside
- Niacin
- Nicotinamide / niacinamide
- Resveratrol
- Coenzyme Q10
- Alpha-lipoic acid
- Creatine
Skincare comparators:
- Niacinamide
- Nicotinamide riboside
- NAD+ topical concepts
- Peptides
- Retinoids
- Vitamin C
- Coenzyme Q10
Medical / pharma comparator categories:
- Glucose-lowering therapies
- Sleep-focused therapeutics
- Performance-related pharmacologic categories
- Age-related frailty intervention categories
- Dermatologic anti-aging ingredient categories
Combination Context
NMN + exercise:
This combination has been studied because researchers want to know whether improving NAD-related status adds to training adaptation or aerobic performance (Research). A randomized study in amateur runners reported improved aerobic-capacity-related outcomes during exercise training, but that does not establish universal exercise-enhancement effects in all populations (Research).
NMN + healthy aging interventions:
Several older-adult studies effectively place NMN in the context of broader healthy-aging research, examining outcomes such as lower-limb function, drowsiness, walking-related measures, and sleep quality (Research) (Research). The main limitation is that these studies remain short and modest in size (Review).
NMN + metabolic-health targeting:
The prediabetes trial shows why NMN is often discussed alongside metabolic interventions (Research). Even in that setting, the best-supported conclusion is a population-specific insulin-sensitivity finding rather than a broadly replicated universal glycemic effect (Review).
NMN + skincare formulation systems:
Topical NMN has been studied in a yeast-fermented filtrate formulation using artificial skin membrane and cell-based testing (Research). This is a formulation-science context rather than a proven human skincare combination strategy (Research).
FAQ
What is NMN?
NMN is nicotinamide mononucleotide, a nucleotide in the NAD+ biosynthesis pathway (Research). In human research, it is mainly studied as an oral NAD+ precursor rather than as a conventional drug with a fully characterized pharmacokinetic dossier (Research). It is also being explored in topical skincare research, but that topical evidence is much earlier than the oral biomarker evidence (Research).
What does human research study NMN for?
Human trials have studied NMN for blood NAD-related biomarker changes, insulin sensitivity, exercise performance, sleep-related outcomes, and broader aging-related functional measures (Research) (Research). Those are the main evidence areas visible in the human studies and reviews used in this article (Review). Topical NMN skin research is emerging, but direct human topical cosmetic trials are not yet the main evidence base (Research).
What are the best-supported uses?
The best-supported findings are that oral NMN can raise NAD-related biomarkers and that it may improve muscle insulin sensitivity in a specific prediabetic postmenopausal population (Research) (Research). Those findings are better supported than broad claims about general anti-aging, universal metabolic improvement, or visible skincare outcomes (Review). Topical NMN is best described as early-stage rather than best-supported (Research).
Is topical NMN effective for skin?
Topical NMN is biologically plausible but not yet well proven in human cosmetic trials (Research). NMN-specific evidence includes artificial membrane permeation testing, reconstructed human skin pigmentation modeling, and animal photoaging research rather than large human trials measuring wrinkles, hydration, firmness, or pigmentation (Research) (Research). The most conservative conclusion is that topical NMN is an emerging skincare research topic, not an established human topical active with a confirmed effective dose (Research).
Why is NMN appearing in skincare products?
NMN is appearing in skincare because it is connected to NAD+ biology, and NAD+ is involved in cellular energy, stress-response pathways, and repair-related biology (Research). Skin-aging research often focuses on oxidative stress, UV-related damage, collagen biology, pigmentation, and barrier function, which makes NAD-related ingredients attractive for formulation research (Research). However, a plausible biological rationale does not prove that topical NMN improves visible skin aging in humans (Research).
Does topical NMN work because it penetrates the skin?
A 2025 NMN study reported permeation through an artificial skin membrane model, but that does not prove the same level of penetration or visible benefit in living human skin (Research). The study is useful because it examined NMN localization, fibroblast collagen Type I response, and stability in a cosmetic formulation context (Research). The safer conclusion is that topical NMN has early permeability and formulation evidence, while human clinical confirmation is still limited (Research).
What skin results are expected from topical NMN based on current evidence?
Current evidence does not support a firm list of expected human skin results from topical NMN. The NMN-specific literature points to early research questions around permeability, collagen-related cell assays, pigmentation models, oxidative stress, and UV-related animal photoaging, but those do not equal proven human outcomes (Research) (Research). Claims about wrinkles, hydration, firmness, barrier repair, or pigmentation should remain cautious until direct human topical NMN trials are available.
What is the difference between NMN and niacinamide in skincare?
NMN and niacinamide are both related to NAD+ biology, but they are different compounds with different evidence bases (Review). Niacinamide has direct topical human cosmetic trials, including studies using 4–5% formulations for pigmentation and visible skin-aging outcomes, while topical NMN evidence is currently earlier and mostly model-based (Research) (Research). Niacinamide evidence should not be used as proof that topical NMN produces the same effects (Review).
Where is evidence mixed or limited?
Evidence is mixed for broad glucose, lipid, cardiometabolic, and general performance claims across pooled adult populations (Review). Reviews in 2024 reported either mixed or non-significant overall findings for several metabolic outcomes even though some individual trials were positive (Review). Topical NMN evidence is limited because direct human topical efficacy trials are not yet well established (Research).
How quickly does NMN act?
The evidence supports acute biological activity after oral administration because acute studies measured changes in clinical parameters and nicotinamide metabolite-related measures after dosing (Research). The current literature does not establish a precise clinical onset for benefits such as improved sleep, function, insulin sensitivity, or visible skin changes (Research) (Research). Topical NMN onset for cosmetic outcomes is not established in direct human trials (Research).
What affects absorption and variability?
The available evidence suggests that variability is influenced by population, dose band, duration, and outcome measured (Review). Positive findings are clearer in some targeted groups than in pooled analyses of mixed adults (Research). For topical NMN, variability would also be expected to depend on formulation, vehicle, stability, and skin delivery, but direct human topical data remain limited (Research).
Is tolerance reported?
The current evidence set does not provide strong evidence for classical tolerance or loss of effect over time. What it does show is that repeated short-term oral use was generally well tolerated in the published human studies available here (Research) (Research). Topical NMN tolerability should not be assumed from oral NMN trials or from niacinamide trials because the formulation and route differ (Research).
Why do studies disagree?
Studies disagree because they use different populations, doses, durations, and endpoints (Review). A trial aimed at muscle insulin sensitivity in a targeted metabolic subgroup can be positive even when broader pooled analyses across mixed adults are neutral or mixed (Research) (Review). Topical NMN claims can also look stronger than the evidence supports when model-based findings are presented like human cosmetic outcomes (Research).
What ingredients is NMN commonly compared with or combined with?
In oral research, NMN is commonly compared conceptually with other NAD-related ingredients such as nicotinamide riboside and niacinamide, but those ingredients are not identical (Review). In exercise research, NMN has been studied alongside training because researchers tested whether NMN supplementation adds to training-related performance outcomes (Research). In skincare, niacinamide is the more evidence-developed topical comparator, while NMN remains earlier-stage (Research).
What foods naturally contain NMN?
The evidence set used here supports NMN as an endogenous biochemical intermediate, but it does not provide a strong directly cited food-composition source detailed enough for a precise foods list in this article (Research). For that reason, this article does not give a food-content table from the current source set.
How is NMN regulated?
In the United States, NIH ODS notes FDA’s November 2022 position that NMN may not be legally marketed as a dietary supplement because it had been authorized for investigation as a new drug (NIH ODS). In the EU, Commission material states that NMN is considered a novel food because prior EU consumption before 15 May 1997 had not been established (EFSA). Product category matters because oral supplements, novel foods, cosmetics, and investigational drug contexts are not regulated the same way.
Resources
- Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men — PubMed — https://pubmed.ncbi.nlm.nih.gov/31685720/
- Chronic nicotinamide mononucleotide supplementation elevates blood NAD levels and alters muscle function in healthy older men — PubMed — https://pubmed.ncbi.nlm.nih.gov/35927255/
- Efficacy and safety of β-nicotinamide mononucleotide supplementation in healthy middle-aged adults — PubMed — https://pubmed.ncbi.nlm.nih.gov/36482258/
- NMN improves muscle insulin sensitivity in prediabetic women — Science — https://www.science.org/doi/10.1126/science.abe9985
- NMN and aerobic capacity in amateur runners — PubMed — https://pubmed.ncbi.nlm.nih.gov/35441939/
- NMN in older adults with diabetes and impaired physical performance — PubMed — https://pubmed.ncbi.nlm.nih.gov/38279614/
- Systematic review of randomized controlled trials on NMN supplementation — PubMed — https://pubmed.ncbi.nlm.nih.gov/39221308/
- NMN effects on glucose and lipid metabolism — PubMed — https://pubmed.ncbi.nlm.nih.gov/39531138/
- Topical NMN artificial membrane permeability study — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC12048825/
- NMN in reconstituted human skin with aged melanocytes — PubMed — https://pubmed.ncbi.nlm.nih.gov/35610161/
- Niacinamide topical clinical evidence review — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC8389214/
- Niacinamide aging facial skin study — PubMed — https://pubmed.ncbi.nlm.nih.gov/16029679/
- NIH ODS Niacin Fact Sheet with NMN regulatory note — NIH ODS — https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
- Novel food consultation request for NMN — European Commission — https://food.ec.europa.eu/system/files/2022-10/novel-food_consult-status_nmn-cz.pdf
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
